FDA grants Priority Review to GW's Epidiolex for seizures

On Thursday, GW Pharmaceuticals plc (NASDAQ:GWPH) said FDA accepted and granted Priority Review to an NDA for Epidiolex cannabidiol as

Read the full 207 word article

User Sign In